Cargando...
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt...
Guardado en:
| Publicado en: | Blood Adv |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7013263/ https://ncbi.nlm.nih.gov/pubmed/32045474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000268 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|